Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Akero Therapeutics to $33 from $70 and keeps an Overweight rating on the shares. The firm is also removing Akero as its Top Pick. While the Phase 2b SYMMETRY study in F4 NASH disappointed, failing to meet the primary endpoint, Morgan Stanley views the totality of the data as supportive and awaits longer week 96 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKRO:
- 89bio price target lowered to $27 from $34 at RBC Capital
- 89bio down 27% after Akero reports NASH trial data
- Akero Therapeutics reports 36-week analysis of Phase 2b SYMMETRY study
- Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
- Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology